Nanobiotix S.A.
NBTX
Rank in Stocks
#6682
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Share Price
$32.03
Last synced: 2026-11-09
Market Cap
$1.63B
Change (1 day)
4.57%
Change (1 year)
48.42%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nanobiotix S.A. (NBTX)
Category
Healthcare
Operating Margin for Nanobiotix S.A. (NBTX)
Operating Margin as of November 2026 TTM: -367.66%
According to Nanobiotix S.A.'s latest financial reports, its current operating margin (TTM) is -367.66%. At the end of 2025 the company had an operating margin of -36.49%.
Operating Margin history for Nanobiotix S.A. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -367.66% | 907.56% |
| 2025 | -36.49% | -106.19% |
| 2024 | 589.13% | -761.28% |
| 2023 | -89.09% | -91.57% |
| 2022 | -1,057.22% | -99.80% |
| 2021 | -525,790.00% | 621.68% |
| 2020 | -72,856.00% | 0.71% |
| 2019 | -72,341.18% | 8,270.50% |
| 2018 | -864.24% | 27.31% |
| 2017 | -678.83% | 68.40% |
| 2016 | -403.10% | -5.58% |
| 2015 | -426.92% | 22.97% |
| 2014 | -347.18% | -92.15% |
| 2013 | -4,422.79% | -36.35% |
| 2012 | -6,948.91% | 1,708.34% |
| 2011 | -384.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.10% |
US
|
|
| -149.01% | -99.59% |
US
|
|
| 25.57% | -100.07% |
AU
|
|
| 31.23% | -100.08% |
BE
|
|
| 29.35% | -100.08% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nanobiotix S.A.'s operating margin
What is Nanobiotix S.A.'s operating margin?
Nanobiotix S.A.'s operating margin is -367.66%, as of Nov 2026.
What was Nanobiotix S.A.'s operating margin in 2025?
In 2025, Nanobiotix S.A.'s operating margin was -36.49%, compared with 589.13% in 2024.
How has Nanobiotix S.A.'s operating margin changed since 2020?
From 2020 to 2025, Nanobiotix S.A.'s operating margin was highest in 2024 (589.13%) and lowest in 2021 (-525,790.00%).
How does Nanobiotix S.A.'s operating margin compare with similar companies?
Nanobiotix S.A.'s operating margin (-367.66%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.